Among the infectious complications observed with the use of immunosuppressive therapies for MS, JC polyomavirus (JCPyV)-associated progressive multifocal leukoencephalopathy (PML) is the primary concern, in particular with the alpha-4 integrin blocking monoclonal antibody natalizumab. 1 Until December 2018, 804 cases (overall around four cases per 1000 patients treated, higher risk if certain risk factors are present) have been reported with the use of natalizumab. Also with other compounds for therapy of MS, an increasing number of PML cases have been reported, although the overall risk is rather low: as of September 2018, 6 cases (around 0.02 per 1000 patients treated) with the use of dimethyl fumarate have been communicated, and, as of August 2018, 23 (around 0.09 per 1000 patients) with fingolimod. For calculation of these numbers, patients who developed symptoms of PML within 3-6 months of cessation of therapy with natalizumab, so-called carry-over cases, were excluded, as natalizumab is generally considered causal in these instances. Recently, the respective marketing authorization holder (MAH) communicated carryover cases of PML after switching natalizumab (n = 6) and fingolimod (n = 1) to ocrelizumab, and after switching natalizumab to alemtuzumab (n = 3), with the first of these alemtuzumab carry-over cases ending fatal. 2 While treatment with ocrelizumab or alemtuzumab was not considered causative in carryover cases, its impact on morbidity and mortality of PML remained elusive.
In this issue of the journal, Gerevini et al. 3 present a case of alemtuzumab-associated PML in monotherapy, occurring 2 months after the second cycle of alemtuzumab infusions. The patient had an 8-year history of MS. She had been treated with interferonbeta, glatiramer acetate, fingolimod (max. 1 year), and dimethyl fumarate (max. 2 years) in the past, and due to continued disease activity was started on alemtuzumab. Fourteen months after her first and 2 months after her second cycle she developed symptoms (two generalized tonic-clonic seizures) and imaging findings suggestive of PML. She therefore did not fulfill any carry-over definition. As correctly judged by the authors, the case met the criteria of definite PML with compatible clinical and magnetic resonance imaging (MRI) findings and the detection of JCPyVdeoxyribonucleic acid (DNA) in the cerebrospinal fluid (CSF) 3, 4 and has to be attributed to the use of alemtuzumab. Fortunately, despite the development of typical signs of immune reconstitution inflammatory syndrome early on, JCPyV-DNA became undetectable in CSF already 1 month after the diagnosis of PML, and the patient recovered but was left disabled with a right-sided hemianopsia. 3 The authors provide a detailed analysis of immunological changes in the peripheral blood of the patient presented. With polymerase chain reaction (PCR)-based methods, they report comparably low thymic output and release of new B cells from the bone marrow. Using flow cytometry, these findings were corroborated by showing a predominant depletion of naïve T cells, including CD4 + CD31 + so-called recent T emigrants. Further analyses using CDR3 spectratyping and next-generation sequencing demonstrated a restricted T and B cell receptor repertoire. 3 Several aspects of this case are remarkable. It is the first case of alemtuzumab-associated PML not confounded by prior use of natalizumab, and even the first such case reported with use of a depleting, pulsed therapy applied in short cycles without recent antecedent exposure to other incriminated immunosuppressive agents. According to the MAH, since approval through July 2018, around 22,000 patients have been treated with alemtuzumab. This corresponds with a low-risk estimate of around 0.04 per 1000 patients.
Alemtuzumab is an anti-CD52 monoclonal antibody that induces a rapid depletion of circulating T and B lymphocytes in peripheral blood, with the lowest numbers occurring within a few days of treatment initiation. 5 Repopulation for B cells sets in earlier and starts already after 3 months of therapy and has been linked to the frequent occurrence of secondary autoimmune complications. 6 By contrast, T cells recover slowly and generally do not reach baseline values at the time of re-dosing after 12 months. 5 This profound impact of alemtuzumab on circulating lymphocytes which has been likened to a rebooting of an abnormal immune system in MS underlies the high therapeutic efficacy with disease control being achieved in a majority of patients even years after discontinuation. The short pulsed treatment regimens obviating the need for continuous application required for other MS disease-modifying drugs such as natalizumab and fingolimod have been suggested to be protective with regard to the development of PML, as the immune system might recover prior to manifestation of this complication to execute immune surveillance, even in individuals with asymptomatic persistent infection with JCPyV, the causative pathogen. With publication of this report, this concept may no longer hold up in its absoluteness, and more post-marketing data need to be awaited prior to drawing firm conclusions. This has implication also for other pulsed therapies for MS, such as cladribine that similarly depletes B and T cells, although kinetics of repopulation are different. 7 Furthermore, the case might provide new insights into PML pathogenesis. Natalizumab and alemtuzumab fundamentally differ in their mode of action: natalizumab associates with lymphocytosis, alemtuzumab with profound lymphopenia. Accordingly, natalizumab-associated cases of PML have been shown to exhibit a normally distributed T cell receptor repertoire at the time of diagnosis in blood, 8 while the alemtuzumab-related case showed restrictions of the T and B cell receptor repertoires. 3 Among the many unanswered questions in PML pathogenesis, the relevant reservoir for the persistent asymptomatic infection with JCPyV is yet to be defined. It has been hypothesized that therapy with natalizumab, but also repopulation after use of depleting agents, may be associated with mobilization of JCPyV-infected pre-B cells from the bone marrow. These pre-B cells may carry the virus to the brain and cause PML. 9 Previous studies, however, were suggestive of altered homing to, rather than true mobilization of pre-B cells from the bone marrow in patients treated with natalizumab. 10 The blood surrogate markers of a limited release of new B cells from the bone marrow, below the levels of healthy controls, at time of PML manifestation in the alemtuzumab-associated case of PML, 3 may be another piece in the puzzle arguing against the intriguing hypothesis of the bone marrow as relevant reservoir of JCPyV for the later development of PML.
The detailed description of this first report of PML following alemtuzumab therapy, not confounded by preceding therapy with natalizumab, sheds light on the complex pathogenesis of PML, in which suppression of the adaptive immunity by the treatment is causal, along with putative genetic and environmental predisposing factors. As consequence for clinical practice, high vigilance for autoimmune and infectious complications should also include the rare differential diagnosis of PML.
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